Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides-Reference-Cited by-同舟云学术

Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides

Published:2018-08-29 Issue:4 Volume:3 Page:
ISSN:2379-5042
Container-title:mSphere
language:en
Short-container-title:mSphere

Author:

Tan Charles Y.¹,Immermann Fred W.²,Sebastian Shite³,Pride Michael W.²,Pavliakova Danka²,Belanger Kelly A.²,Watson Wendy¹,Scott Daniel A.²,Sidhu Mohinder²,Jansen Kathrin U.²,Giardina Peter C.²

Affiliation:

1. Pfizer Inc., Collegeville, Pennsylvania, USA

2. Pfizer Inc., Pearl River, New York, USA

3. Affinivax, Cambridge, Massachusetts, USA

Abstract

The pneumococcal enzyme-linked immunosorbent assay (ELISA) measures IgG antibodies in human serum, and it is an important assay that supports licensure of pneumococcal vaccines. The immune correlate of protection, 0.35 µg/ml of IgG antibodies, was determined by the ELISA method. Pfizer has developed a new Luminex-based assay platform to replace the ELISA. These papers describe the important work of (i) validating the Luminex-based assay and (ii) bridging the immune correlate of protection (0.35 µg/ml IgG) to equivalent values reported by the Luminex platform.

Funder

Pfizer

Publisher

American Society for Microbiology

Subject

Molecular Biology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mSphere.00127-18

Reference27 articles.

1. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children

2. A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV Infection

3. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial